Rectal misoprostol and oxytocin versus oxytocin only in preventing postpartum haemorrhage

Efficacy and safety of rectal misoprostol and oxytocin versus oxytocin only in preventing postpartum haemorrhage in at-risk women in Asaba: a double-blind randomized controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202512770937526

Enrollment

114

Registered

2025-12-17

Start date

2025-12-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary postpartum haemorrhage

Interventions

Rectal misoprostol plus oxytocin infusion

oxytocin infusion plus placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Grand multiparity -Polyhydramnios -Fetal macrosomia -Chorioamnionitis -Precipitate labour -Previous PPH -Induced/ Augmented labour -Use of magnesium sulphate -Maternal age>35yrs -Medical conditions e.g. diabetes mellitus and hypertensive disorders of pregnancy.

Exclusion criteria

Exclusion criteria: haematocrit < 30% -presenting in 2nd and 3rd stages of labour -perineal and cervical lacerations -women without risk factor for uterine atony - contraindications to prostaglandin use

Design outcomes

Primary

Measure	Time frame
proportion of women with post-partum blood loss of equal to or > 500ml.	—

Secondary

Measure	Time frame
significant change in pre- and post-delivery haematocrit -the need for additional uterotonics -the need for blood transfusion . -the need for ICU admission -side effects of medications like pyrexia and shivering	—

Countries

Nigeria

Contacts

Public ContactAmechi Nwosa

Senior Registrar

drmechosky@gmail.com+2348033508794

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026